Amphastar Pharmaceuticals, Inc.
AMPHAmphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Drugs in Pipeline
14
Phase 3 Programs
6
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
22dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How AMPH's past catalysts played out
Epinephrine inhalation aerosol
Asthma
I004
Pharmacokinetics
E004 (Epinephrine Inhalation Aerosol) HFA-MDI
Asthma
Epinephrine HFA-MDI (E004)
Asthma
Primatene Mist
Asthma
NovoLog
Pharmacokinetics
Proventil® MDI
Asthma
A006
Asthma
Arm T1: Primatene Mist HFA
Asthma
albuterol inhalation powder
Asthma
Albuterol DPI 25 mcg/inh
Asthma
A006 DPI
Asthma
Epinephrine Inhalation Aerosol, HFA
Asthma
Hyaluronidase
Allergic Skin Reaction
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Epinephrine inhalation aerosol | Phase 3 | Asthma | - | - |
I004 | Phase 3 | Pharmacokinetics | - | - |
E004 (Epinephrine Inhalation Aerosol) HFA-MDI | Phase 3 | Asthma | - | - |
Epinephrine HFA-MDI (E004) | Phase 3 | Asthma | - | - |
Primatene Mist | Phase 3 | Asthma | - | - |
NovoLog | Phase 3 | Pharmacokinetics | - | - |
Proventil® MDI | Phase 2 | Asthma | - | - |
A006 | Phase 2 | Asthma | - | - |
Arm T1: Primatene Mist HFA | Phase 2 | Asthma | - | - |
albuterol inhalation powder | Phase 2 | Asthma | - | - |
Albuterol DPI 25 mcg/inh | Phase 2 | Asthma | - | - |
A006 DPI | Phase 2 | Asthma | - | - |
Epinephrine Inhalation Aerosol, HFA | Phase 2 | Asthma | - | - |
Hyaluronidase | Phase 2 | Allergic Skin Reaction | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Amphastar Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 14 drug candidates in Amphastar Pharmaceuticals, Inc.'s (AMPH) pipeline across Phase 3, Phase 2. Its lead program is Epinephrine inhalation aerosol (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Amphastar Pharmaceuticals, Inc.'s next FDA catalyst?→
Amphastar Pharmaceuticals, Inc.'s (AMPH) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AMPH biotech catalysts?→
Add AMPH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Amphastar Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.